Broadridge discloses 9.99% stake in Tharimmune
Tharimmune, Inc. received a beneficial ownership report from Broadridge Financial Solutions, Inc., which now reports control over 4,187,548 shares of Tharimmune common stock through warrants exercisable within sixty days.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tharimmune, Inc. received a beneficial ownership report from Broadridge Financial Solutions, Inc., which now reports control over 4,187,548 shares of Tharimmune common stock through warrants exercisable within sixty days. This represents 9.99% of Tharimmune’s common stock, calculated using 37,729,847 shares outstanding as of January 17, 2026 plus the warrant shares.
The warrants are subject to a 9.99% ownership blocker in a Subscription Agreement, so an additional 13,070,680 shares issuable under the warrants are not counted in Broadridge’s beneficial ownership. The securities are owned of record by Broadridge Securities Processing Solutions, LLC, with Broadridge Financial Solutions, Inc. holding voting and dispositive power, and the filing states the stake is held on a passive, non‑control basis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Tharimmune (THAR) does Broadridge report on this Schedule 13G?
How are Broadridge’s 9.99% Tharimmune (THAR) holdings structured?
Is Broadridge’s 9.99% position in Tharimmune (THAR) a passive investment?
Who actually holds the Tharimmune (THAR) warrants reported by Broadridge?
How did Broadridge calculate its 9.99% ownership of Tharimmune (THAR)?
AI-generated analysis. How Rhea-AI works. Not financial advice.